← Scroll for more →
Idexx Laboratories Inc (IDXX)
In Vitro & In Vivo Diagnostic Substances
Latest Price
$575.98
TTM P/E
40.48
Normalized P/E
53.17
TTM Div Yield
--
Fwd Div Yield
--
Book Value
20.44
P/B Ratio
28.18
Valuation metrics
adjust assumptions →EPS: $13.08
Book value / share: $20.14
Formula: √(22.5 × EPS × BVPS)
Graham Number
$76.99
87% downside
Norm. op. income: $932M (median of 7yr)
Tax rate: 20%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$90.16
84% downside
Base FCF: $773M (median of recent 5yr)
Growth: 21%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$547.31
5% downside
EPS: $13.08
Target P/E: 53×
Formula: EPS × P/E
P/E Fair Value
$693.24
+20% upside
Institutional Ownership
92.8% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.17M | $4.30B | 10.36% | -195.4K | 2026-06-30 |
| Vanguard Capital Management LLC | 5.15M | $2.71B | 6.53% | -30.3K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 3.90M | $2.05B | 4.94% | -14.3K | 2026-06-30 |
| State Street Corp | 3.75M | $1.97B | 4.75% | +74.5K | 2026-06-30 |
| Invesco Ltd. | 3.61M | $1.90B | 4.58% | +1.93M | 2026-06-30 |
| Geode Capital Management, LLC | 2.56M | $1.34B | 3.25% | -98.1K | 2026-06-30 |
| Bamco Inc | 1.98M | $1.04B | 2.51% | +343.4K | 2026-06-30 |
| Morgan Stanley | 1.36M | $713.0M | 1.72% | +40.1K | 2026-06-30 |
| Bank of New York Mellon Corp | 1.19M | $628.0M | 1.51% | -311.2K | 2026-06-30 |
| Arrowstreet Capital, Limited Partnership | 1.07M | $561.0M | 1.35% | +228.2K | 2026-06-30 |